Janux Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Janux Therapeutics, Inc. (JANX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $2.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-06
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $500.00K, a 28.57% decline year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $1.70M, a 43.33% decline year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $2.40M, a 89.79% decline year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $600.00K, a 90.48% decline year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $6.70M, a 85.31% decline from fiscal 2024.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $45.60M, a 2300.00% increase from fiscal 2023.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $1.90M, a 1800.00% increase from fiscal 2022.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $100.00K, a 90.00% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.20M 10-Q · filed 2026-08-06 | $4.60M derived: sum of 3 quarters · filed 2026-08-06 | $5.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.70M 10-Q · filed 2026-05-07 | $4.10M derived: sum of 2 quarters · filed 2026-05-07 | $4.70M derived: sum of 3 quarters · filed 2026-05-07 | $5.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.00M derived: sum of 2 quarters · filed 2026-02-26 | $3.70M derived: sum of 3 quarters · filed 2026-08-06 | $6.70M 10-K · filed 2026-02-26 |
| 2025-09-30 | $600.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.30M derived: sum of 2 quarters · filed 2026-08-06 | $4.30M 10-Q · filed 2025-11-06 | $27.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.70M 10-Q · filed 2026-08-06 | $27.20M derived: sum of 3 quarters · filed 2026-08-06 | $33.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.00M 10-Q · filed 2026-05-07 | $26.50M derived: sum of 2 quarters · filed 2026-05-07 | $32.80M derived: sum of 3 quarters · filed 2026-05-07 | $43.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $23.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $29.80M derived: sum of 2 quarters · filed 2026-02-26 | $40.00M derived: sum of 3 quarters · filed 2026-02-26 | $45.60M 10-K · filed 2026-02-26 |
| 2024-09-30 | $6.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $16.50M derived: sum of 2 quarters · filed 2025-11-06 | $22.10M 10-Q · filed 2025-11-06 | $22.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $10.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $15.80M 10-Q · filed 2025-08-07 | $15.80M derived: sum of 3 quarters · filed 2026-02-26 | $16.20M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $5.60M 10-Q · filed 2025-05-08 | $5.60M derived: sum of 2 quarters · filed 2026-02-26 | $6.00M derived: sum of 3 quarters · filed 2026-02-26 | $6.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $400.00K derived: sum of 2 quarters · filed 2026-02-26 | $400.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.90M 10-K · filed 2026-02-26 |
| 2023-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $400.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.90M 10-Q · filed 2024-11-06 | $1.90M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $1.50M 10-Q · filed 2024-08-07 | $1.50M derived: sum of 3 quarters · filed 2025-02-27 | $1.50M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.50M 10-Q · filed 2024-05-08 | $1.50M derived: sum of 2 quarters · filed 2025-02-27 | $1.50M derived: sum of 3 quarters · filed 2025-02-27 | $1.50M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 derived: sum of 3 quarters · filed 2025-02-27 | $100.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $100.00K 10-Q · filed 2023-11-07 | $100.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $100.00K 10-Q · filed 2023-08-08 | $100.00K derived: sum of 3 quarters · filed 2023-08-08 | $100.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $100.00K 10-Q · filed 2023-05-09 | $100.00K derived: sum of 2 quarters · filed 2023-05-09 | $100.00K derived: sum of 3 quarters · filed 2023-05-09 | $100.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $0.00 derived: sum of 2 quarters · filed 2023-03-10 | $0.00 derived: sum of 3 quarters · filed 2023-03-10 | $1.00M 10-K · filed 2023-03-10 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $1.00M 10-Q · filed 2022-11-10 | $1.00M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.00M 10-Q · filed 2022-08-09 | $1.00M derived: sum of 3 quarters · filed 2022-08-09 | $1.00M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $1.00M 10-Q · filed 2022-05-10 | $1.00M derived: sum of 2 quarters · filed 2022-05-10 | $1.00M derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $0.00 derived: sum of 2 quarters · filed 2022-03-18 | $0.00 10-K · filed 2022-03-18 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |